{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T19:00:10Z","timestamp":1792004410826,"version":"4.4.0"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T00:00:00Z","timestamp":1726531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012737","name":"Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012737","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012399","name":"Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100021704","name":"Administration for Strategic Preparedness and Response","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Taniborbactam is a boronate-based \u03b2-lactamase inhibitor in clinical development in combination with cefepime.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Cefepime\u2013taniborbactam and comparator broth microdilution MICs were determined for patient isolates of Enterobacterales (n\u200a=\u200a20\u200a725) and Pseudomonas aeruginosa (n\u200a=\u200a7919) collected in 59 countries from 2018 to 2022. Taniborbactam was tested at a fixed concentration of 4 mg\/L. Isolates with cefepime\u2013taniborbactam MICs\u200a\u2265\u200a16 mg\/L underwent WGS. \u03b2-Lactamase genes were identified in additional meropenem-resistant isolates by PCR\/Sanger sequencing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Taniborbactam reduced the cefepime MIC90 value for all Enterobacterales from &amp;gt;16 to 0.25 mg\/L (&amp;gt;64-fold). At \u226416 mg\/L, cefepime\u2013taniborbactam inhibited 99.5% of all Enterobacterales isolates; &amp;gt;95% of isolates with MDR and ceftolozane\u2013tazobactam-resistant phenotypes; \u200a\u2265\u200a89% of isolates with meropenem-resistant and difficult-to-treat-resistant (DTR) phenotypes; &amp;gt;80% of isolates with meropenem\u2013vaborbactam-resistant and ceftazidime\u2013avibactam-resistant phenotypes; 100% of KPC-positive, 99% of OXA-48-like-positive, 99% of ESBL-positive, 97% of acquired AmpC-positive, 95% of VIM-positive and 76% of NDM-positive isolates. Against P. aeruginosa, taniborbactam reduced the cefepime MIC90 value from 32 to 8 mg\/L (4-fold). At \u226416 mg\/L, cefepime\u2013taniborbactam inhibited 96.5% of all P. aeruginosa isolates; 85% of meropenem-resistant phenotype isolates; 80% of isolates with MDR and meropenem\u2013vaborbactam-resistant phenotypes; &amp;gt;70% of isolates with DTR, ceftazidime\u2013avibactam-resistant and ceftolozane\u2013tazobactam-resistant phenotypes; and 82% of VIM-positive isolates. Multiple potential mechanisms of resistance, including carriage of IMP, or alterations in PBP3 (ftsI), porins (decreased permeability) and efflux (up-regulation) were present in most isolates with cefepime\u2013taniborbactam MICs\u200a\u2265\u200a16 mg\/L.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Cefepime\u2013taniborbactam exhibited potent in vitro activity against Enterobacterales and P. aeruginosa, and inhibited most carbapenem-resistant isolates, including those carrying serine carbapenemases or NDM\/VIM MBLs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkae329","type":"journal-article","created":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T23:42:56Z","timestamp":1725406976000},"page":"3116-3131","source":"Crossref","is-referenced-by-count":29,"title":["Cefepime\u2013taniborbactam activity against antimicrobial-resistant clinical isolates of Enterobacterales and\n                    <i>Pseudomonas aeruginosa<\/i>\n                    : GEARS global surveillance programme 2018\u201322"],"prefix":"10.1093","volume":"79","author":[{"given":"James A","family":"Karlowsky","sequence":"first","affiliation":[{"name":"IHMA , Schaumburg, IL ,","place":["USA"]},{"name":"Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba , Winnipeg, MB ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7356-1851","authenticated-orcid":false,"given":"Mark G","family":"Wise","sequence":"additional","affiliation":[{"name":"IHMA , Schaumburg, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith A","family":"Hackel","sequence":"additional","affiliation":[{"name":"IHMA , Schaumburg, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A","family":"Six","sequence":"additional","affiliation":[{"name":"Venatorx Pharmaceuticals, Inc. , Malvern, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6994-4286","authenticated-orcid":false,"given":"Tsuyoshi","family":"Uehara","sequence":"additional","affiliation":[{"name":"Venatorx Pharmaceuticals, Inc. , Malvern, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis M","family":"Daigle","sequence":"additional","affiliation":[{"name":"Venatorx Pharmaceuticals, Inc. , Malvern, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel C","family":"Pevear","sequence":"additional","affiliation":[{"name":"Venatorx Pharmaceuticals, Inc. , Malvern, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7827-7227","authenticated-orcid":false,"given":"Greg","family":"Moeck","sequence":"additional","affiliation":[{"name":"Venatorx Pharmaceuticals, Inc. , Malvern, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel F","family":"Sahm","sequence":"additional","affiliation":[{"name":"IHMA , Schaumburg, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,9,17]]},"reference":[{"key":"2024121304531777000_dkae329-B1","doi-asserted-by":"publisher","first-page":"e0116823","DOI":"10.1128\/aac.01168-23","article-title":"Structural basis of metallo-\u03b2-lactamase resistance to taniborbactam","volume":"68","author":"Drusin","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"2024121304531777000_dkae329-B2","doi-asserted-by":"publisher","first-page":"e01963-19","DOI":"10.1128\/AAC.01963-19","article-title":"VNRX-5133 (taniborbactam), a broad-spectrum inhibitor of serine- and metallo-\u03b2-lactamases, restores activity of cefepime in Enterobacterales and Pseudomonas aeruginosa","volume":"64","author":"Hamrick","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2024121304531777000_dkae329-B3","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1093\/jac\/dkaa391","article-title":"Activity of \u03b2-lactam\/taniborbactam (VNRX-5133) combinations against carbapenem-resistant Gram-negative bacteria","volume":"76","author":"Mushtaq","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2024121304531777000_dkae329-B4","doi-asserted-by":"publisher","first-page":"e0033923","DOI":"10.1128\/aac.00339-23","article-title":"Impact of acquired broad-spectrum \u03b2-lactamases on susceptibility to novel combinations made of \u03b2-lactams (aztreonam, cefepime, meropenem, and imipenem) and novel \u03b2-lactamase inhibitors in Escherichia coli and Pseudomonas aeruginosa","volume":"67","author":"Le Terrier","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"2024121304531777000_dkae329-B5","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1056\/NEJMoa2304748","article-title":"Cefepime\u2013taniborbactam in complicated urinary tract infection","volume":"390","author":"Wagenlehner","year":"2024","journal-title":"N Engl J Med"},{"key":"2024121304531777000_dkae329-B6","author":"Clinical Trials","year":"2024"},{"key":"2024121304531777000_dkae329-B7","author":"CLSI"},{"key":"2024121304531777000_dkae329-B8","author":"CLSI"},{"key":"2024121304531777000_dkae329-B9","author":"EUCAST"},{"key":"2024121304531777000_dkae329-B10","doi-asserted-by":"publisher","first-page":"e0128122","DOI":"10.1128\/aac.01281-22","article-title":"In vitro activity of cefepime\u2013taniborbactam and comparators against clinical isolates of Gram-negative bacilli from 2018 to 2020: results from the global evaluation of antimicrobial resistance via surveillance (GEARS) program","volume":"67","author":"Karlowsky","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"2024121304531777000_dkae329-B11","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1093\/cid\/ciy378","article-title":"Difficult-to-treat resistance in Gram-negative bacteremia at 173 US hospitals: retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents","volume":"67","author":"Kadri","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2024121304531777000_dkae329-B12","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1099\/jmm.0.000667","article-title":"Ram locus is a key regulator to trigger multidrug resistance in Enterobacter aerogenes","volume":"67","author":"Molitor","year":"2018","journal-title":"J Med Microbiol"},{"key":"2024121304531777000_dkae329-B13","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1093\/jac\/dku568","article-title":"Characterization of Escherichia coli NDM isolates with decreased susceptibility to aztreonam\/avibactam: role of a novel insertion in PBP3","volume":"70","author":"Alm","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2024121304531777000_dkae329-B14","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1128\/CMR.00117-14","article-title":"The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria","volume":"28","author":"Li","year":"2015","journal-title":"Clin Microbiol Rev"},{"key":"2024121304531777000_dkae329-B15","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1089\/mdr.2015.0122","article-title":"Reduced susceptibility to cefepime in clinical isolates of Enterobacteriaceae producing OXA-1 \u03b2-lactamase","volume":"22","author":"Torres","year":"2016","journal-title":"Microb Drug Resist"},{"key":"2024121304531777000_dkae329-B16","doi-asserted-by":"publisher","first-page":"e01589-17","DOI":"10.1128\/AAC.01589-17","article-title":"Genomics and susceptibility profiles of extensively drug-resistant Pseudomonas aeruginosa isolates from Spain","volume":"61","author":"Del Barrio-Tofi\u00f1o","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2024121304531777000_dkae329-B17","doi-asserted-by":"publisher","first-page":"22002","DOI":"10.1073\/pnas.1013092107","article-title":"Structural basis for effectiveness of siderophore-conjugated monocarbams against clinically relevant strains of Pseudomonas aeruginosa","volume":"107","author":"Han","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024121304531777000_dkae329-B18","doi-asserted-by":"publisher","first-page":"685","DOI":"10.3389\/fmicb.2018.00685","article-title":"The versatile mutational resistome of Pseudomonas aeruginosa","volume":"9","author":"L\u00f3pez-Causap\u00e9","year":"2018","journal-title":"Front Microbiol"},{"key":"2024121304531777000_dkae329-B19","doi-asserted-by":"publisher","first-page":"8649","DOI":"10.1128\/JB.01342-06","article-title":"Nald encodes a second repressor of the mexAB-oprM multidrug efflux operon of Pseudomonas aeruginosa","volume":"188","author":"Morita","year":"2006","journal-title":"J Bacteriol"},{"key":"2024121304531777000_dkae329-B20","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1128\/AAC.02622-15","article-title":"Amino acid substitutions account for most MexS alterations in clinical nfxC mutants of Pseudomonas aeruginosa","volume":"60","author":"Richardot","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2024121304531777000_dkae329-B21","doi-asserted-by":"publisher","first-page":"e02445-17","DOI":"10.1128\/AAC.02445-17","article-title":"Constitutive activation of MexT by amino acid substitutions results in MexEF-OprN overproduction in clinical isolates of Pseudomonas aeruginosa","volume":"62","author":"Juarez","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2024121304531777000_dkae329-B22","doi-asserted-by":"publisher","first-page":"e66236","DOI":"10.1371\/journal.pone.0066236","article-title":"Nfxb as a novel target for analysis of mutation spectra in Pseudomonas aeruginosa","volume":"8","author":"Monti","year":"2013","journal-title":"PLoS One"},{"key":"2024121304531777000_dkae329-B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/2049-632X.12208","article-title":"Pseudomonas aeruginosa AmpR: an acute-chronic switch regulator","volume":"73","author":"Balasubramanian","year":"2015","journal-title":"Pathog Dis"},{"key":"2024121304531777000_dkae329-B24","doi-asserted-by":"publisher","first-page":"6349","DOI":"10.1128\/AAC.01388-12","article-title":"Genetic markers of widespread extensively drug-resistant Pseudomonas aeruginosa high-risk clones","volume":"56","author":"Cabot","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2024121304531777000_dkae329-B25","doi-asserted-by":"publisher","first-page":"3890","DOI":"10.1128\/JB.01997-14","article-title":"Structural and functional characterization of Pseudomonas aeruginosa global regulator AmpR","volume":"196","author":"Caille","year":"2014","journal-title":"J Bacteriol"},{"key":"2024121304531777000_dkae329-B26","doi-asserted-by":"publisher","first-page":"3856","DOI":"10.1128\/AAC.03113-15","article-title":"Elucidation of mechanisms of ceftazidime resistance among clinical isolates of Pseudomonas aeruginosa by using genomic data","volume":"60","author":"Kos","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2024121304531777000_dkae329-B27","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1093\/cid\/ciz173","article-title":"A primer on AmpC \u03b2-lactamases: necessary knowledge for an increasingly multidrug-resistant world","volume":"69","author":"Tamma","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2024121304531777000_dkae329-B28","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1016\/S1473-3099(20)30868-9","article-title":"The urgent need for metallo-\u03b2-lactamase inhibitors: an unattended global threat","volume":"22","author":"Mojica","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2024121304531777000_dkae329-B29","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.jgar.2021.08.010","article-title":"In vitro activity of ceftazidime\/avibactam and comparators against carbapenemase-producing Enterobacterales and Pseudomonas aeruginosa isolates collected globally between 2016 and 2018","volume":"27","author":"Kiratisin","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"2024121304531777000_dkae329-B30","author":"Centers for Disease Control and Prevention"},{"key":"2024121304531777000_dkae329-B31","doi-asserted-by":"publisher","first-page":"dlab197","DOI":"10.1093\/jacamr\/dlab197","article-title":"Activity of cefepime\/taniborbactam and comparators against whole genome sequenced ertapenem-non-susceptible Enterobacterales clinical isolates: CANWARD 2007\u201319","volume":"4","author":"Golden","year":"2022","journal-title":"JAC Antimicrob Resist"},{"key":"2024121304531777000_dkae329-B32","doi-asserted-by":"publisher","first-page":"e0216121","DOI":"10.1128\/aac.02161-21","article-title":"In vitro activity of cefepime\u2013taniborbactam against carbapenemase-producing Enterobacterales and Pseudomonas aeruginosa isolates recovered in Spain","volume":"66","author":"Hern\u00e1ndez-Garc\u00eda","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2024121304531777000_dkae329-B33","doi-asserted-by":"publisher","first-page":"106440","DOI":"10.1016\/j.ijantimicag.2021.106440","article-title":"In vitro comparative activity of the new beta-lactamase inhibitor taniborbactam with cefepime or meropenem against Klebsiella pneumoniae and cefepime against Pseudomonas aeruginosa metallo-beta-lactamase-producing clinical isolates","volume":"58","author":"Meletiadis","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"2024121304531777000_dkae329-B34","doi-asserted-by":"publisher","first-page":"e106228","DOI":"10.1016\/j.ijantimicag.2020.106228","article-title":"Potent inhibitory activity of taniborbactam towards NDM-1 and NDM-1 (Q119X) mutants and in vitro activity of cefepime\/taniborbactam against MBL producing Enterobacterales","volume":"57","author":"Piccirilli","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"2024121304531777000_dkae329-B35","doi-asserted-by":"publisher","first-page":"e0167621","DOI":"10.1128\/AAC.01676-21","article-title":"Assessment of activity and resistance mechanisms to cefepime in combination with the novel \u03b2-lactamase inhibitors zidebactam, taniborbactam, and enmetazobactam against a multicenter collection of carbapenemase-producing Enterobacterales","volume":"66","author":"V\u00e1zquez-Ucha","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2024121304531777000_dkae329-B36","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1093\/jac\/dkaa053","article-title":"In vitro activity of the novel \u03b2-lactamase inhibitor taniborbactam (VNRX-5133) in combination with cefepime or meropenem against MDR Gram-negative bacterial isolates from China","volume":"75","author":"Wang","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2024121304531777000_dkae329-B37","doi-asserted-by":"publisher","first-page":"e0492522","DOI":"10.1128\/spectrum.04925-22","article-title":"In vitro activity of two cefepime-based novel combinations, cefepime\/taniborbactam and cefepime\/zidebactam, against carbapenemase-expressing Enterobacterales collected in India","volume":"11","author":"Bakthavatchalam","year":"2023","journal-title":"Microbiol Spectr"},{"key":"2024121304531777000_dkae329-B38","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s10096-023-04697-4","article-title":"Deciphering mechanisms affecting cefepime\u2013taniborbactam in vitro activity in carbapenemase-producing Enterobacterales and carbapenem-resistant Pseudomonas spp. isolates recovered during a surveillance study in Spain","volume":"43","author":"Hern\u00e1ndez-Garc\u00eda","year":"2024","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2024121304531777000_dkae329-B39","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1093\/jac\/dkac241","article-title":"Activity of cefiderocol, imipenem\/relebactam, cefepime\/taniborbactam and cefepime\/zidebactam against ceftolozane\/tazobactam- and ceftazidime\/avibactam-resistant Pseudomonas aeruginosa","volume":"77","author":"Lasarte-Monterrubio","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2024121304531777000_dkae329-B40","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/S1473-3099(23)00069-5","article-title":"NDM-9 resistance to taniborbactam","volume":"23","author":"Le Terrier","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"2024121304531777000_dkae329-B41","doi-asserted-by":"publisher","first-page":"e0099123","DOI":"10.1128\/aac.00991-23","article-title":"Relative inhibitory activities of the broad-spectrum \u03b2-lactamase inhibitor taniborbactam against metallo-\u03b2-lactamases","volume":"68","author":"Le Terrier","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"2024121304531777000_dkae329-B42","doi-asserted-by":"publisher","first-page":"e0057923","DOI":"10.1128\/aac.00579-23","article-title":"New boronate drugs and evolving NDM-mediated beta-lactam resistance","volume":"67","author":"Lomovskaya","year":"2023","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/12\/3116\/60930237\/dkae329.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/12\/3116\/60930237\/dkae329.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T23:53:30Z","timestamp":1734047610000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/79\/12\/3116\/7759345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,17]]},"references-count":42,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,9,17]]},"published-print":{"date-parts":[[2024,12,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkae329","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12]]},"published":{"date-parts":[[2024,9,17]]}}}